Hepln-13 是具有口服活性的Hepsin抑制剂(IC50:0.33 μM)。它可用于研究转移性前列腺癌。

Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.

Hepln-13 (10 μM; 2 hours; 293 cells) inhibits cleavage[1].

HepIn-13 displays dose-dependent inhibition of Hepsin overexpression-relevant prostate cancer phenotypes in LPB-Tag/PB-Hepsin mice and blocks prostate cancer metastasis in this animal model.

64369-13-7

C17H13BrN2

325.2

Hepln 13;Hepln13

DMSO:60 mg/mL (184.50 mM,Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years